anti tissue factor monoclonal antibody morab 066

Drug Overview

The anti-tissue factor monoclonal antibody MORAb-066 is an investigational drug designed to target a specific protein on the surface of cancer cells. Because it uses the body’s immune system proteins (antibodies) to specifically identify and attack cancer cells, this medication is classified as both a Targeted Therapy and a form of Immunotherapy.

• Generic Name: anti-tissue factor monoclonal antibody MORAb-066 (MORAb-066)
• US Brand Names: None (Investigational drug)
• Drug Class: Humanized Monoclonal Antibody (Targeted Therapy / Immunotherapy)
• Route of Administration: Intravenous (IV) Infusion
• FDA Approval Status: Not FDA Approved. This drug is strictly investigational and has only been evaluated in clinical trials.
  
  Explore the targeted anti tissue factor monoclonal antibody morab 066. Our medical hospital offers expert guidance and personalized care.

What Is It and How Does It Work? (Mechanism of Action)

To understand how MORAb-066 works, we must first look at a protein called Tissue Factor (TF). Under normal conditions, TF is a transmembrane protein that helps the blood clot when you get a cut. However, in many types of cancer, tumors produce abnormally high levels of Tissue Factor. The cancer uses this protein to build new blood vessels (angiogenesis), spread to other parts of the body (metastasis), and grow faster.

MORAb-066 works at the molecular level to stop this process:

1. Binding to the Target: When MORAb-066 enters the bloodstream, it actively seeks out and binds directly to the Tissue Factor (TF) proteins located on the surface of tumor cells and tumor blood vessels.
2. Blocking Coagulation Factors: By covering the TF protein, the antibody acts like a shield. It physically prevents another protein, called Coagulation Factor VIIa (FVIIa), from attaching to TF.
3. Stopping the Chain Reaction: Because FVIIa cannot bind to TF, the next step in the sequencethe activation of Factor X (FX) into FXais blocked. This prevents the formation of thrombin, a key enzyme in blood clotting.
4. Tumor Starvation and Control: By blocking these specific signaling pathways, MORAb-066 helps prevent cancer-associated blood clots (thrombosis). More importantly, it cuts off the signals that tell the tumor to grow and create new blood vessels, essentially starving the cancer cells.

FDA-Approved Clinical Indications

Because MORAb-066 is an investigational drug, it does not currently have any FDA-approved indications for public use. However, it has been studied in clinical trials for the following areas:

Investigational Oncological Uses

• Advanced or Metastatic Breast Cancer
• Advanced or Metastatic Pancreatic Cancer
• Advanced or Metastatic Colorectal Cancer
• Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Investigational Non-Oncological Uses

• None. (The primary focus of this drug’s research has been entirely on oncology and tumor-related blood clots.

Dosage and Administration Protocols

Note: Because MORAb-066 is an experimental drug, there is no standard commercial dosage. The information below reflects the protocols used in Phase 1 clinical trials (such as study NCT01761240).

Clinical Efficacy and Research Results

When evaluating the clinical efficacy of MORAb-066 between 2020 and 2025, it is important to note that the core clinical trials for this specific drug were halted in their early phases (Phase 1). Therefore, large-scale numerical datasuch as overall survival rates or exact disease progression percentagesdo not exist for this specific antibody.

However, the research gathered from early MORAb-066 trials has been highly valuable to the medical community. The Phase 1 studies proved that targeting Tissue Factor is a viable strategy in oncology. While MORAb-066 itself did not advance to Phase 3 trials, the biological principles it tested have paved the way for newer, successful Tissue Factor-targeting drugs (such as antibody-drug conjugates) that are now showing positive tumor shrinkage and survival benefits in modern clinical settings.

Safety Profile and Side Effects

Because MORAb-066 interferes with the body’s clotting mechanism, its side effect profile requires strict monitoring by healthcare professionals.

Common Side Effects (>10%)

• Infusion-Related Reactions: Chills, fever, or mild allergic responses during the IV drip.
• Mild Bleeding: Minor nosebleeds (epistaxis) or bleeding gums.
• General Symptoms: Fatigue, mild nausea, or headache.

Serious Adverse Events

• Severe Hemorrhage: Because the drug blocks blood clotting, there is a risk of severe internal bleeding, including coughing up blood (hemoptysis), vomiting blood (hematemesis), or bleeding in the gastrointestinal tract.
• Immune System Reactions: The body may develop anti-drug antibodies (ADAs), which can cause severe allergic reactions or make the drug stop working.

Black Box Warning

As an unapproved drug, MORAb-066 does not carry an official FDA Black Box Warning. However, clinical trial safety protocols treat severe bleeding and hemorrhage as the primary, life-threatening risk associated with this class of medication.

Management Strategies

If bleeding occurs, the infusion is stopped immediately. Doctors will provide supportive care, which may include blood transfusions or clotting factors. If an allergic reaction happens during the IV drip, nurses will pause the medication and administer antihistamines or steroids.

Research Areas: Connection to Regenerative Medicine

While MORAb-066 is not directly used in stem cell therapy or regenerative medicine, its targetTissue Factor (TF)is heavily researched in these fields. Tissue Factor plays a critical role in how blood vessels form and repair themselves. Current research is exploring how blocking TF in the tumor microenvironment can stop cancer cells from hijacking the body’s natural regenerative processes. By combining anti-TF therapies with modern Immunotherapy, researchers hope to reprogram the immune system to recognize and destroy tumors more efficiently without causing unwanted bleeding.

Patient Management and Practical Recommendations

For patients participating in clinical trials for anti-Tissue Factor therapies, strict management guidelines are followed to ensure safety.

Pre-Treatment Tests

• Coagulation Profile: Blood tests like PT/PTT must be normal to ensure the patient’s blood can still clot properly.
• Organ Function Panels: Liver enzymes (ALT/AST) and kidney tests (creatinine) must be checked.
• Urinalysis: To check for hidden blood in the urine.

Precautions During Treatment

Patients with a history of severe bleeding, stomach ulcers, or those taking systemic blood thinners (like warfarin or heparin) are generally not allowed to receive this treatment due to the high risk of severe hemorrhage.

Do’s and Don’ts

• DO use a soft-bristled toothbrush and an electric razor to avoid accidental cuts.
• DO report any signs of unusual bruising, pink or red urine, or dark, tarry stools to your doctor immediately.
• DON’T take aspirin, ibuprofen, or other non-steroidal anti-inflammatory drugs (NSAIDs) without your doctor’s permission, as these can increase bleeding risks.
• DON’T participate in contact sports or activities with a high risk of physical injury while the drug is in your system.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. MORAb-066 is an investigational compound and is not approved by the FDA or other global regulatory agencies for the treatment of any disease. Patients should always consult with a qualified, licensed healthcare professional or oncologist regarding treatment options, clinical trials, and medication safety. Do not disregard professional medical advice or delay seeking it because of information provided on this website.